(2008). An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat
(2009). Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors.
(2007). Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res
(2001). Børresen-Dale A-L: Gene expression patterns of breast carcinomas distuinguish tumor subclasses with clinical implications. Proc Natl Acad Sci
(2011). Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat
(2000). E, O’Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res
(2009). Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Human Pathol
(2009). Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature.
(1996). Expression of Most Matrix Metalloproteinase Family Members in Breast Cancer Represents a Tumor-Induced Host Response.
(2002). Expression of proteinases and inhibitors in human breast cancer progression and survival. J Clin Pathol: Mol Pathol
(2006). Fountzilas G: Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol
(2007). Garcia-Muniz JL: Study of matrix metalloproteinases and their inhibitors in breast cancer.
(2005). Genes that mediate breast cancer metastasis to lung. Nature
(2000). Interstitial Collagenases as Markers of Tumor Progression. Clin Cancer Res
(1991). IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology
(2002). Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Science
(1999). Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol
(2009). Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat
(2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev
(2009). Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer.
(2008). MJ: Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol
(2006). Mobashery S: Design and Characterization of a Metalloproteinase Inhibitor-Tethered Resin for the Detection of Active MMPs in Biological Samples. Chemistry & Biology
(2000). Molecular portraits of human breast tumours. Nature
(2008). Moriuchi T: High MMP-1 mRNA Expression is a Risk Factor for Disease-Free and Overall Survivals in Patients with Invasive Breast Carcinoma.
(2006). Polymorphismus of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP9 in breast cancer. Breast Cacer Res Treat
Sapino A: WHO Classification of Tumours.
(2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research
(2010). Triple-Negative Breast Cancer.
(2008). Vizoso F: Androgen receptor expression in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors.
(2010). Vizoso F: Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer.
(2010). Vizoso F: Expression of metalloproteases and their inhibitors in different histological types of breast cancer.
(2000). Weinberg RA: The hallmarks of cancer. Cell
(2002). Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer